175 related articles for article (PubMed ID: 9816271)
41. High frequency of frameshift mutation on p53 gene in Taiwanese with non small cell lung cancer.
Chang MY; Chong IW; Chen FM; Wang JY; Cheng TL; Cheng YJ; Sheu CC; Hung SY; Yang MC; Lin SR
Cancer Lett; 2005 May; 222(2):195-204. PubMed ID: 15863268
[TBL] [Abstract][Full Text] [Related]
42. The ras gene family in human non-small-cell lung cancer.
Slebos RJ; Rodenhuis S
J Natl Cancer Inst Monogr; 1992; (13):23-9. PubMed ID: 1327034
[TBL] [Abstract][Full Text] [Related]
43. FHIT and p53 gene abnormalities in bronchioloalveolar carcinomas. Correlations with clinicopathological data and K-ras mutations.
Marchetti A; Pellegrini S; Bertacca G; Buttitta F; Gaeta P; Carnicelli V; Nardini V; Griseri P; Chella A; Angeletti CA; Bevilacqua G
J Pathol; 1998 Mar; 184(3):240-6. PubMed ID: 9614374
[TBL] [Abstract][Full Text] [Related]
44. Prognostic role of K-Ras mutations in non-small cell lung cancer: still an issue for open debate.
Neri M; Cesario A; Granone P; Dominioni L; Puntoni R; D'Angelillo RM; Russo P
Lung Cancer; 2006 Sep; 53(3):393-5; author reply 397-8. PubMed ID: 16887233
[TBL] [Abstract][Full Text] [Related]
45. K-ras gene mutation is a useful predictor of the survival of early stage colorectal cancers.
Lee JC; Wang ST; Lai MD; Lin YJ; Yang HB
Anticancer Res; 1996; 16(6B):3839-44. PubMed ID: 9042267
[TBL] [Abstract][Full Text] [Related]
46. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment.
Marchetti A; Martella C; Felicioni L; Barassi F; Salvatore S; Chella A; Camplese PP; Iarussi T; Mucilli F; Mezzetti A; Cuccurullo F; Sacco R; Buttitta F
J Clin Oncol; 2005 Feb; 23(4):857-65. PubMed ID: 15681531
[TBL] [Abstract][Full Text] [Related]
47. K-ras and p16(INK4A)alterations in sputum of NSCLC patients and in heavy asymptomatic chronic smokers.
Destro A; Bianchi P; Alloisio M; Laghi L; Di Gioia S; Malesci A; Cariboni U; Gribaudi G; Bulfamante G; Marchetti A; Bosari S; Infante M; Ravasi G; Roncalli M
Lung Cancer; 2004 Apr; 44(1):23-32. PubMed ID: 15013580
[TBL] [Abstract][Full Text] [Related]
48. Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung.
Rodenhuis S; van de Wetering ML; Mooi WJ; Evers SG; van Zandwijk N; Bos JL
N Engl J Med; 1987 Oct; 317(15):929-35. PubMed ID: 3041218
[TBL] [Abstract][Full Text] [Related]
49. K-ras mutations in lung tumors from p53 mutant mice exposed to cigarette smoke.
Yao R; Wang Y; D'Agostini F; Izzotti A; Lubet RA; You M; De Flora S
Exp Lung Res; 2005 Mar; 31(2):271-81. PubMed ID: 15824025
[TBL] [Abstract][Full Text] [Related]
50. TP53 mutation, allelism and survival in non-small cell lung cancer.
Nelson HH; Wilkojmen M; Marsit CJ; Kelsey KT
Carcinogenesis; 2005 Oct; 26(10):1770-3. PubMed ID: 15905205
[TBL] [Abstract][Full Text] [Related]
51. Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women.
Gealy R; Zhang L; Siegfried JM; Luketich JD; Keohavong P
Cancer Epidemiol Biomarkers Prev; 1999 Apr; 8(4 Pt 1):297-302. PubMed ID: 10207632
[TBL] [Abstract][Full Text] [Related]
52. A universal method for the mutational analysis of K-ras and p53 gene in non-small-cell lung cancer using formalin-fixed paraffin-embedded tissue.
Sarkar FH; Valdivieso M; Borders J; Yao KL; Raval MM; Madan SK; Sreepathi P; Shimoyama R; Steiger Z; Visscher DW
Diagn Mol Pathol; 1995 Dec; 4(4):266-73. PubMed ID: 8634783
[TBL] [Abstract][Full Text] [Related]
53. [Mutations of ras and p53 genes in human non-small cell lung cancer cell lines and their clinical significance].
Mitsudomi T; Oyama T; Gazdar AF; Minna JD; Okabayashi K; Shirakusa T
Nihon Geka Gakkai Zasshi; 1992 Sep; 93(9):944-7. PubMed ID: 1361656
[TBL] [Abstract][Full Text] [Related]
54. [Evaluation of the prognostic significance of P53 mutation in patients with non-small cell lung cancer].
Jassem E; Rosell R; Jassem J; Monzo M; Kobierska G; Badzio A; Roszkiewicz A; Skokowski J; Szulc A
Pneumonol Alergol Pol; 1998; 66(5-6):290-6. PubMed ID: 9857649
[TBL] [Abstract][Full Text] [Related]
55. Occurrence of ras mutations in human lung cancer. Minireview.
Vachtenheim J
Neoplasma; 1997; 44(3):145-9. PubMed ID: 9372854
[TBL] [Abstract][Full Text] [Related]
56. Detection of K-ras oncogene mutations by polymerase chain reaction-based ligase chain reaction.
Lehman TA; Scott F; Seddon M; Kelly K; Dempsey EC; Wilson VL; Mulshine JL; Modali R
Anal Biochem; 1996 Aug; 239(2):153-9. PubMed ID: 8811898
[TBL] [Abstract][Full Text] [Related]
57. Comparison of oncogene mutation detection and telomerase activity for the molecular staging of non-small cell lung cancer.
Ahrendt SA; Yang SC; Wu L; Westra WH; Jen J; Califano JA; Sidransky D
Clin Cancer Res; 1997 Jul; 3(7):1207-14. PubMed ID: 9815801
[TBL] [Abstract][Full Text] [Related]
58. K-ras oncogene activation in atypical alveolar hyperplasias of the human lung.
Westra WH; Baas IO; Hruban RH; Askin FB; Wilson K; Offerhaus GJ; Slebos RJ
Cancer Res; 1996 May; 56(9):2224-8. PubMed ID: 8616876
[TBL] [Abstract][Full Text] [Related]
59. Increased prevalence of K-ras oncogene mutations in lung adenocarcinoma.
Mills NE; Fishman CL; Rom WN; Dubin N; Jacobson DR
Cancer Res; 1995 Apr; 55(7):1444-7. PubMed ID: 7882350
[TBL] [Abstract][Full Text] [Related]
60. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy.
Schiller JH; Adak S; Feins RH; Keller SM; Fry WA; Livingston RB; Hammond ME; Wolf B; Sabatini L; Jett J; Kohman L; Johnson DH
J Clin Oncol; 2001 Jan; 19(2):448-57. PubMed ID: 11208838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
